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FOCUS REVIEW
“Doctors and patients know what works and what does
not.”
(C. Vargas, February 27, 2008, PLoS Medicine)
“Clinical practice plus millions of content patients can't
be that wrong.”
(R. Werner, February 27, 2008, PLoS Medicine)
On February 26, 2008, PLoS Medicine published a
meta-analysis that my colleagues and I had conducted
on antidepressant medication (1). Most meta-analyses
suffer from publication bias, which can happen when
pharmaceutical companies withhold unsuccessful trials
from publication (2, 3). To circumvent this, we used the
Freedom of Information act in the U.S. to obtain the
data on all clinical trials submitted to the Food and Drug
Administration (FDA) for the licensing of the four new-
generation antidepressants.
The results of our meta-analysis showed that people
got better on medication, but they also got better on
placebo, and the difference between the two was small.
In fact, it was below the criterion for clinical
significance established by the National Institute for
Health and Clinical Excellence (NICE), which sets
treatment guidelines for the National Health Service in
the UK. Clinical significance was found only in a few
relatively small studies conducted on patients with
extremely severe levels of depression.
This study was the subject of widespread media
attention, especially in the UK, where it was front page
news in most of the national daily newspapers (4). Not
surprisingly, it stirred considerable controversy. In this
article, I examine some of the reactions to the meta-
analysis.
“PLACEBOS COULD NOT PRODUCE EFFECTS
LIKE THESE”
Placebo effects can be surprisingly strong. Placebos
can reverse the effects of powerful medications. They
can affect the body as well as the mind. They produce
side effects as well as beneficial effects. They can
produce symptoms and alleviate them. In this section, I
look at the power of belief to produce profound changes
in people’s experience.
One of the earliest reports on the power of placebo
was the seminal work of Stewart Wolf, who
demonstrated the ability of placebos to block the effect
of potent drugs (5). A pioneer in the investigation of
placebo effects, Wolf reported three successful
experimental attempts at reversing the effects of active
medications that typically induce abdominal
discomfort. In each case, the reversal was brought about
by misinforming the subject about the nature of the drug
being administered, and in each case the subjective
changes were verified by physiological assessment. One
of Wolf's subjects was a 28-year-old pregnant woman
who was suffering from nausea and vomiting. Wolf
gave her ipecac, a drug that interrupts normal gastric
contractions, thereby inducing vomiting and nausea.
Although ipecac is commonly used to induce vomiting
when toxic substances have been swallowed, Wolf
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misinformed his patient that it was a medicine which
would alleviate her nausea. Prior to taking ipecac, the
patient displayed an absence of gastric contractions.
Within 20 minutes of ingesting the drug, normal gastric
contractions resumed and the nausea ended.
Placebos have been reported to produce some rather
startling effects on skin conditions. The most
impressive of these reports involves the suggestion-
related production and inhibition of contact dermatitis
(6). Contact dermatitis is a skin condition produced by
chemical substances to which people have become
sensitized. In the study reported by Ikemi and
Nakagawa, 13 students were touched on one arm with
leaves from a harmless tree, but were told that the
leaves were from a lacquer or wax tree (Japanese trees
that produce effects similar to poison ivy and to which
the boys had reported being hypersensitive). On the
other arm, the subjects were touched with poisonous
leaves, which they were led to believe were from a
harmless tree. All 13 subjects displayed a skin reaction
to the harmless leaves (the placebo), but only two
reacted to the poisonous leaves.
Although a meta-analysis published in the New
England Journal of Medicine concluded that the
placebo effect is not very powerful (7), Wampold and
his colleagues have reanalyzed those data and
calculated the number needed to treat (NNT) for
placebo compared to no treatment at all (8). NNT is the
number of patients that need to be treated to achieve one
success by means of a particular treatment. So the
smaller the NNT, the larger the effect. Compared to no-
treatment, the NNT for placebo is 7.Although this is not
a large effect, it is instructive to compare it to the NNT
for various accepted medical treatments, as published in
a growing database of published studies provided online
(http://www.cebm.utoronto.ca/glossary/nntsPrint.htm)
by the University of Toronto’s Centre for Evidence-
Based Medicine. The NNT for radiotherapy for breast
cancer, for example, is shown on that database to be 8,
that for beta-blockers for chronic heart failure is 24, the
flu vaccine has an NNT of 12, and aspirin as a
prophylactic for myocardial infarction has an NNT of
208.
The NNT of 7 for placebo treatment was calculated
across studies of many different clinical conditions. But
there is good reason to believe that the placebo effect
should be even greater on depression. This is because
hopelessness is a core feature of depression, and one of
the presumed effects of a placebo is to instill hope (9).
If you ask depressed patients what the worst thing in
their life is, many will tell you that it is their depression.
They feel stuck in an intolerable condition and they are
hopeless about the possibility of getting better (10). So
it stands to reason that a treatment promising relief
would bring some relief, merely on the basis of hope-
instilling promise. Indeed, a meta-analysis of the
published antidepressant literature indicates that the
placebo effect (placebo – no-treatment) is twice as large
as the drug effect (drug – placebo) (11).
“ANTIDEPRESSANTS WORK IN CLINICAL
PRACTICE”
Clinical experience shows that antidepressant drugs
work, in the sense that patients get better when given
medication. So do our meta-analyses. Patients given
antidepressants in the clinical trials showed substantial
and clinically significant improvement, as did those
given placebo. Physicians do not generally prescribe
placebos to their patients. Hence they have no way of
comparing the effects of the drugs they prescribe to
placebos. When they prescribe a treatment and it works,
quite naturally they ascribe the cure to the treatment.
But the history of medicine is replete with cures that
were “known” to work by doctors and their patients.
These apparently effective treatments, that we now
consider to have been placebos, include dolphin’s
genitalia, lizard’s blood, crocodile dung, pig's teeth,
putrid meat, frog’s sperm, powdered stone, human
sweat, worms, and spiders. That is why placebo-
controlled trials are required in order to demonstrate
drug efficacy. When the administration of a drug is
followed by improvement, the improvement might not
be due to the drug’s chemical composition. Placebo-
controlled trials are used to separate the drug effect
from such factors as the placebo effect, spontaneous
remission, and regression towards the mean.
“YOU HAVEN’T PROVEN THAT
ANTIDEPRESSANTS DON’T WORK”
This is absolutely true. In fact, our data show a small
advantage for drug over placebo that is statistically
significant, but not clinically significant. But I will
extend this criticism. Not only haven’t we proven that
antidepressants don’t work, but we also haven’t proven
that their effect is below the threshold of clinical
significance. What we have shown is that the data upon
which drug approval was based does not show clinical
significance. But it is always possible that future
studies, perhaps with better experimental methods or
measures of depression, will show a greater effect.
Possibility is a long way from fact, however. The
onus should not be on critics to demonstrate that a
treatment is ineffective, but rather for proponents to
demonstrate that it is. If all that is needed is an absence
of proof that a treatment does not work, then perhaps we
ought to resume using treatments crocodile dung and
dolphin genitalia until well-enough designed clinical
trials prove conclusively that they are not more effective
than placebo.Antidepressants and the Placebo Effect 221 Vol. 11 No. 2
“ANTIDEPRESSANTS DRUGS MIGHT WORK
FOR SOME PEOPLE BUT NOT OTHERS”
This is indeed possible. In fact, we found evidence of
greater drug effectiveness in a small subset of studies
involving patients with exceptionally high levels of
initial depression, although it seemed that they were less
responsive to the placebo, rather than more responsive
to the drug. We also found that the drug-placebo
difference was zero for people who were moderately
depressed. For this rather large group of sufferers, anti-
depressants seemed to have no drug effect at all.
It is feasible that there are other subgroups of patients
for which antidepressants are more effective, but simply
asserting this possibility is not enough. One must
identify those subgroups and demonstrate the clinically-
significant benefit they obtain from active medication
over placebo. Some of the data for doing so have
already been collected. For example, gender is most
certainly identified in the data sets of most, if not all,
clinical trials. It would be a simple matter, for example,
to reanalyze these data to test whether women are in fact
more responsive to SSRIs and men to tricylic
medication, as has been suggested (12).
Note that if there are some groups of patients that
respond better than the overall mean, then there must
also be some that respond worse. Given how small the
advantage is over placebo overall, this should be of
considerable concern. If some are responding
substantially better, then others must not be responding
at all—or even being made worse by the active
medication, compared to how they would have fared on
placebo. If this is the case, it would be important to
know it so that antidepressant medication could be
prescribed more selectively.
Understandably, pharmaceutical companies might be
reluctant to carry out analyses of this sort, as they have
the potential to cut into sales substantially. One way
around this is to require that raw data for all approved
medications be available for researchers to reanalyze.
This could easily be done with full protection of the
anonymity of those who participated as subjects.
Greater transparency and availability of the data would
be in the best interests of patients, doctors, third-party
payers, health researchers, and government agencies.
“THE CLINICAL TRIALS ARE FLAWED”
Defenders of antidepressants have noted a number of
flaws in the clinical trials used to evaluate them. One is
that the patients in these trials were not depressed
enough. In fact, using the American Psychiatric
Association classification scheme, the mean baseline
severity was in the very severe range for all but one of
the trials we analyzed. The one exception was a clinical
trial involving moderately depressed patients, in which
the response to drug was virtually identical to the
response to placebo.
“Very severe” is the most severe category in the
classification scheme. So how can it be asserted that the
patients were not depressed enough? One possibility is
that clinical trial researchers distort the data. According
to a spokesperson for the FDA, patients may be rated as
more severely depressed than they actually are so that
they will qualify for the trial (4). Now if this is true, then
the response of treatment is even less than the clinical
trials indicate, unless of course the researchers also
inflate scores at the end of the trial. Equally troubling is
the idea that researchers are intentionally distorting the
data in any way. These trials are the basis for drug
approval. If the data have been distorted, then perhaps
the drugs should not have been approved in the first
place.
Whereas some critics have complained that the
patients in the clinical trials we assessed were not
depressed enough, others have argued that they were
too depressed. An editorial in Nature Reviews Drug
Discovery, for example, complained that “All but one
trial analyzed involved groups with mean initial
depression scores in the ‘very severe’range, limiting the
strength of extrapolations” (13). Of the two
contradictory criticisms, this is the more cogent. The
drug companies did not conduct any trials on patients
between the very severely depressed and moderately
depressed categories. But here too, the evidence should
be on the companies to demonstrate efficacy for the
severely—but not very severely—depressed patients.
There may be many flaws in clinical trials, including
relatively short durations, unrepresentativeness of the
sample, and the breaking of blind by patients and
doctors on the basis of side effects (14). But these trials
are the data on the basis of which the drugs were
approved. If they are flawed, then we have no evidence
of drug effectiveness, and the drugs should not have
been approved in the first place.
“DON’T ASK; DON’T TELL”
Finally, some have argued that even if the drugs don’t
work, it was wrong of my colleagues and me to publish
our studies. We shouldn’t tell patients that the drugs
don’t work because it will undermine their faith in
treatment. I disagree. Without accurate knowledge,
patients and physicians cannot make informed
treatment decisions, researchers will be asking the
wrong questions, and policymakers will be
implementing misinformed policies. If the
antidepressant effect is largely a placebo effect, it is
important that we know this. It means that improvement
can be obtained without reliance on addictive drugs
with potentially serious side effects (15, 16).McGill Journal of Medicine 222 2008
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